Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | PRKDC | P78527 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991194 | 0.89 | PIK3CG (0.85) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12991843 | 0.88 | PIK3CG (0.64) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12992101 | 0.86 | PIK3CG (0.78) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12991847 | 0.85 | PIK3CG (0.66) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL13004889 | 0.85 | PIK3CG (1.00) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12991941 | 0.85 | PIK3CG (1.00) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12992172 | 0.85 | PIK3CG (1.00) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12992697 | 0.84 | PIK3CG (0.79) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12992178 | 0.83 | PIK3CG (0.60) | PIK3CGCYP2C9KCNH2PRKDC | |
| SCHEMBL12992314 | 0.83 | PIK3CG (1.00) | PIK3CGCYP2C9KCNH2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344153-B2 | Inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344153-B2 | Inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CG, PIK3CD | PIK3CG 2/4885CYP2C9 4190/4885KCNH2 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.